Literature DB >> 21328792

Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis.

Joshua T Swan1, Daniel M Riche, Krista D Riche, Vikas Majithia.   

Abstract

PURPOSE: We performed a systematic review and meta-analysis to compare response rates (complete remission plus partial remission) for nonsteroid immunosuppressant therapy to steroid-only immunosuppressant therapy in patients with membranous lupus nephritis.
METHODS: A literature review was conducted from June 25, 2010 by querying PubMed, MEDLINE, and EMBASE databases. Inclusion criteria were trials containing remission data on patients with confirmed pure class V (Va and Vb) membranous lupus nephritis. The primary analysis evaluates response rates for regimens that contain at least one nonsteroid immunosuppressant therapy and steroid-only immunosuppressant therapy. A proportion meta-analysis using a DerSimonian-Laird random-effects model was performed. Data are reported as pooled proportions in percentages with 95% confidence intervals. Significant heterogeneity and/or bias were compensated for by trial exclusion.
RESULTS: Twenty-four studies met inclusion criteria for meta-analysis, which yielded 34 groups of patients' data. Upon meta-analysis, the response rate for nonsteroid immunosuppressant therapy is higher than for steroids alone (81% [74%-87%] vs 60% [39%-79%]), even when compensating for significant heterogeneity and bias (76% [71%-81%] versus 60% [39%-79%]).
CONCLUSION: Nonsteroid immunosuppressant therapies in combination with steroids seem to be more effective than steroids alone for inducing partial or complete remission in patients with membranous lupus nephritis who have nephrotic proteinuria at baseline. This trial was not able to analyze adverse events, flares, relapses, or patient survival because of underreporting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328792     DOI: 10.2310/JIM.0b013e318204c965

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

1.  Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.

Authors:  Maria Pereira; Eyal Muscal; Karen Eldin; M John Hicks; Anna Carmela P Sagcal-Gironella; Marietta DeGuzman; Scott E Wenderfer
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

2.  Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.

Authors:  Juan Manuel Mejía-Vilet; Bertha M Córdova-Sánchez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-07-30       Impact factor: 2.980

Review 3.  Treatment of severe lupus nephritis: the new horizon.

Authors:  Tak Mao Chan
Journal:  Nat Rev Nephrol       Date:  2014-11-25       Impact factor: 28.314

Review 4.  Biomarkers and updates on pediatrics lupus nephritis.

Authors:  Michael Bennett; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2013-07-16       Impact factor: 2.670

Review 5.  Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.

Authors:  Yuehong Chen; Jianhong Sun; Kun Zou; Yuan Yang; Gang Liu
Journal:  Rheumatol Int       Date:  2017-05-10       Impact factor: 3.580

6.  New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort.

Authors:  Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; Maria G Tektonidou; John Boletis
Journal:  Front Med (Lausanne)       Date:  2022-04-14

7.  Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.

Authors:  A Oglesby; A J Shaul; T Pokora; C Paramore; L Cragin; G Dennis; S Narayanan; A Weinstein
Journal:  Int J Rheumatol       Date:  2013-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.